First-in-human study of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer: Update on safety and pharmacokinetics and initial report on pharmacodynamic responses and clinical benefit

被引：0
|
作者：
Camidge, D. R. [1 ]
Britten, C. D. [2 ]
Schellens, J. H. M. [3 ]
Guo, F. [4 ]
Milham, R. [4 ]
Eckhardt, S. G. [1 ]
Wong, S. G. [2 ]
Boss, D. S. [3 ]
Lucca, J. [5 ]
Jannes, P. A. [5 ]
机构：
[1] Univ Colorado, Denver, CO USA
[2] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Pfizer Global Res & Dev, New London, CT USA
[5] Dana Farber Canc Inst, Boston, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3505S / 3505S
页数：1
相关论文
共 50 条
  • [1] First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer
    Schellens, J. H.
    Britten, C. D.
    Camidge, D. R.
    Boss, D.
    Wong, S.
    Diab, S.
    Guo, F.
    Maguire, R. P.
    Letrent, S. P.
    Eckhardt, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] First-in-human (FIH) study of PF-00299804 in advanced cancer patients: correlation between pharmacokinetics (PK) and pharmacodynamics (PD)
    Schellens, J.
    Guo, F.
    Jaenne, P. A.
    Eckhardt, S. G.
    Camidge, D. R.
    Taylor, I.
    Lucca, J.
    Boss, D. S.
    Wong, S. G.
    Britten, C. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 177 - 178
  • [3] First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics
    Shapiro, G. I.
    Molina, J.
    Bendell, J.
    Brana, I.
    Spicer, J.
    Kwak, E.
    Pandya, S.
    Millham, R.
    Houk, B.
    Bell-McGuinn, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 123 - 123
  • [4] First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics
    Britten, C. D.
    Adjei, A. A.
    Millham, R.
    Houk, B.
    Wainberg, Z. A.
    Guthrie, T.
    Dy, G.
    LoRusso, P. M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 122
  • [5] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Blackhall, Fiona
    Krzakowski, Maciej
    Barrios, Carlos H.
    Park, Keunchil
    Bover, Isabel
    Heo, Dae Seog
    Rosell, Rafael
    Talbot, Denis C.
    Frank, Richard
    Letrent, Stephen P.
    Ruiz-Garcia, Ana
    Taylor, Ian
    Liang, Jane Q.
    Campbell, Alicyn K.
    O'Connell, Joseph
    Boyer, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3337 - 3344
  • [6] Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
    Takahashi, Toshiaki
    Boku, Narikazu
    Murakami, Haruyasu
    Naito, Tateaki
    Tsuya, Asuka
    Nakamura, Yukiko
    Ono, Akira
    Machida, Nozomu
    Yamazaki, Kentaro
    Watanabe, Junichiro
    Ruiz-Garcia, Ana
    Imai, Keiji
    Ohki, Emiko
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2352 - 2363
  • [7] Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
    Toshiaki Takahashi
    Narikazu Boku
    Haruyasu Murakami
    Tateaki Naito
    Asuka Tsuya
    Yukiko Nakamura
    Akira Ono
    Nozomu Machida
    Kentaro Yamazaki
    Junichiro Watanabe
    Ana Ruiz-Garcia
    Keiji Imai
    Emiko Ohki
    Nobuyuki Yamamoto
    Investigational New Drugs, 2012, 30 : 2352 - 2363
  • [8] Efficacy and safety of PF-00299804 (PF299). an oral, irreversible, part-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC)
    Mok, T.
    Spigel, D. R.
    Park, K.
    Socinski, M. A.
    Tung, S. Y.
    Kim, D.
    Borzillo, G.
    Zhang, H.
    O'Connell, J. P.
    Janne, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer (vol 30, pg 3337, 2012)
    Ramalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 399 - 399
  • [10] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
    Shapiro, Geoffrey I.
    Bell-McGuinn, Katherine M.
    Molina, Julian R.
    Bendell, Johanna
    Spicer, James
    Kwak, Eunice L.
    Pandya, Susan S.
    Millham, Robert
    Borzillo, Gary
    Pierce, Kristen J.
    Han, Lixin
    Houk, Brett E.
    Gallo, Jorge D.
    Alsina, Maria
    Brana, Irene
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1888 - 1895
12345